Gemini Therapeutics (GMTX) Issues GEM103 Program Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ANT
3. SPY
4. FFR
5. FFAI
6. TSLA
7. META
8. FICO
9. CART
10. LLY

Go back to Gemini Therapeutics (GMTX) Issues GEM103 Program Update

Gemini Therapeutics Provides GEM103 Program Update

January 10, 2022 8:00 AM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103s clinical development program.

GEM103 Phase 2a ReGAtta Study Update

Ongoing analysis of the 62 patients enrolled in the ReGAtta study continues to show that more than nine months of GEM103 exposure has been generally well-tolerated, able to durably reduce biomarkers of complement activation, and able to... More